In vivo theranostics at the peri-infarct region in cerebral ischemia

Theranostics

Volumn 4, Issue 1, 2014, Pages 90-105

  Agulla, Jesús ^a,b   Brea, David ^a,c   Campos, Francisco ^a   Sobrino, Tomás ^a   Argibay, Bárbara ^a   Al Soufi, Wajih ^d   Blanco, Miguel ^a   Castillo, José ^a   Ramos Cabrer, Pedro ^a  

^a Instituto de Salud Carlos III   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Cerebral ischemia; Drug delivery; MRI; Peri infarct region; Theranostics

Indexed keywords

CITICOLINE; HEAT SHOCK PROTEIN 72; IMMUNOLIPOSOME; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN ISCHEMIA; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DEVELOPED COUNTRY; DISABILITY; FLUORESCENCE; IMAGING SYSTEM; IMMUNOBLOTTING; IMMUNOHISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; LIGHT SCATTERING; MALE; MOLECULAR RECOGNITION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN EXPRESSION; PROTEOMICS; RADIODIAGNOSIS; RADIOTHERAPY; RAT; TRANSMISSION ELECTRON MICROSCOPY;

CEREBRAL ISCHEMIA; DRUG DELIVERY.; MRI; PERI-INFARCT REGION; THERANOSTICS;

ANIMALS; BIOLOGICAL MARKERS; CELLS, CULTURED; CYTIDINE DIPHOSPHATE CHOLINE; HSP72 HEAT-SHOCK PROTEINS; INFARCTION, MIDDLE CEREBRAL ARTERY; LIPOSOMES; MAGNETIC RESONANCE IMAGING; MALE; MICROSCOPY, FLUORESCENCE; NANOCAPSULES; NOOTROPIC AGENTS; OPTICAL IMAGING; PROTEOME; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84896696981     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.7088     Document Type: Article

References (51)

1. Picard FJ, Bergeron MG. Rapid molecular theranostics in infectious diseases. Drug Discov Today. 2002; 7: 1092-101.
2. Fernandez-Fernandez A, Manchanda R, McGoron A. Theranostic Applications of Nanomaterials in Cancer: Drug Delivery, Image-Guided Therapy, and Multifunctional Platforms. Applied Biochemistry and Biotechnology. 2011; 165: 1628-51.
3. Lobatto ME, Fuster V, Fayad ZA, Mulder WJM. Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov. 2011; 10: 835-52.
4. Shim MS, Kwon YJ. Stimuli-responsive polymers and nanomaterials for gene delivery and imaging applications. Advanced Drug Delivery Reviews. 2012; 64: 1046-59.
5. Kinlay S. Changes in Stroke Epidemiology, Prevention, and Treatment. Circulation. 2011; 124: e494-e6.
6. Ramos-Cabrer P, Campos F. Liposomes and nanotechnology in drug development: focus on neurological targets. Int J Nanomed. 2013; 8: 951-60.
7. Adeoye O, Hornung R, Khatri P, Kleindorfer D. Recombinant Tissue-Type Plasminogen Activator Use for Ischemic Stroke in the United States. Stroke. 2011; 42: 1952-5.
8. Lo EH. A new penumbra: transitioning from injury into repair after stroke. Nat Med. 2008; 14: 497-500.
9. Ramos-Cabrer P, Campos F, Sobrino T, Castillo J. Targeting the Ischemic Penumbra. Stroke. 2011; 42: S7-S11.
10. Hata R, Maeda K, Hermann D, Mies G, Hossmann KA. Evolution of brain infarction after transient focal cerebral ischemia in mice. J Cereb Blood Flow Metab. 2000; 20: 937-46.
11. Hill WD, Hess DC, Martin-Studdard A, Carothers JJ, Zheng J, Hale D, et al. SDF-1 (CXCL12) is upregulated in the ischemic penumbra following stroke: association with bone marrow cell homing to injury. J Neuropathol Exp Neurol. 2004; 63: 84-96.
12. Kokubo Y, Matson GB, Liu J, Mancuso A, Kayama T, Sharp FR, et al. Correlation between changes in apparent diffusion coefficient and induction of heat shock protein, cell-specific injury marker expression, and protein synthesis reduction on diffusion-weighted magnetic resonance images after temporary focal cerebral ischemia in rats. J Neurosurg. 2002; 96: 1084-93.
13. Li Y, Chopp M, Garcia JH, Yoshida Y, Zhang ZG, Levine SR. Distribution of the 72-kd heat-shock protein as a function of transient focal cerebral ischemia in rats. Stroke. 1992; 23: 1292-8.
14. Rami A. Upregulation of Beclin 1 in the ischemic penumbra. Autophagy. 2008; 4: 227-9.
15. Sanz O, Estrada A, Ferrer I, Planas AM. Differential cellular distribution and dynamics of HSP70, cyclooxygenase-2, and c-Fos in the rat brain after transient focal ischemia or kainic acid. Neuroscience. 1997; 80: 221-32.
16. Soriano MA, Ferrer I, Rodriguez-Farre E, Planas AM. Expression of c-fos and inducible hsp-70 mRNA following a transient episode of focal ischemia that had non-lethal effects on the rat brain. Brain Res. 1995; 670: 317-20.
17. Shimada IS, Borders A, Aronshtam A, Spees JL. Proliferating reactive astrocytes are regulated by Notch-1 in the peri-infarct area after stroke. Stroke. 2011; 42: 3231-7.
18. Vega VL, Rodríguez-Silva M, Frey T, Gehrmann M, Diaz JC, Steinem C, et al. Hsp70 Translocates into the Plasma Membrane after Stress and Is Released into the Extracellular Environment in a Membrane-Associated Form that Activates Macrophages. The Journal of Immunology. 2008; 180: 4299-307.
19. Gupta A, Cooper ZA, Tulapurkar ME, Potla R, Maity T, Hasday JD, et al. Toll-like receptor agonists and febrile range hyperthermia synergize to induce heat shock protein 70 expression and extracellular release. J Biol Chem. 2013; 288: 2756-66.
20. Allen TM. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci. 1994; 15: 215-20.
21. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999; 51: 691-743.
22. Kabanov AV. Polymer genomics: an insight into pharmacology and toxicology of nanomedicines. Adv Drug Deliv Rev. 2006; 58: 1597-621.
23. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev. 2001; 47: 113-31.
24. Lee CC, MacKay JA, Frechet JM, Szoka FC. Designing dendrimers for biological applications. Nat Biotechnol. 2005; 23: 1517-26.
25. Lu Y, Low PS. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev. 2002; 54: 675-93.
26. Nori A, Kopecek J. Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Adv Drug Deliv Rev. 2005; 57: 609-36.
27. Widera A, Norouziyan F, Shen WC. Mechanisms of TfR-mediated transcytosis and sorting in epithelial cells and applications toward drug delivery. Adv Drug Deliv Rev. 2003; 55: 1439-66.
28. Denora N, Trapani A, Laquintana V, Lopedota A, Trapani G. Recent advances in medicinal chemistry and pharmaceutical technology--strategies for drug delivery to the brain. Curr Top Med Chem. 2009; 9: 182-96.
29. Vlieghe P, Khrestchatisky M. Medicinal Chemistry Based Approaches and Nanotechnology-Based Systems to Improve CNS Drug Targeting and Delivery. Med Res Rev. 2013; 33: 457-516.
30. Ramos-Cabrer P, Agulla J, Argibay B, Perez-Mato M, Castillo J. Serial MRI study of the enhanced therapeutic effects of liposome-encapsulated citicoline in cerebral ischemia. Int J Pharm. 2011; 405: 228-33.
31. Bulte JW, de Cuyper M, Despres D, Frank JA. Short-vs. long-circulating magnetoliposomes as bone marrow-seeking MR contrast agents. J Magn Reson Imaging. 1999; 9: 329-35.
32. Aragnol D, Leserman LD. Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo. Proc Natl Acad Sci U S A. 1986; 83: 2699-703.
33. Gabizon A, Papahadjopoulos D. The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim Biophys Acta. 1992; 1103: 94-100.
34. Torchilin VP, Omelyanenko VG, Papisov MI, Bogdanov AA, Jr., Trubetskoy VS, Herron JN, et al. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim Biophys Acta. 1994; 1195: 11-20.
35. van Rooy I, Cakir-Tascioglu S, Hennink WE, Storm G, Schiffelers RM, Mastrobattista E. In vivo methods to study uptake of nanoparticles into the brain. Pharmaceutical research. 2011; 28: 456-71.
36. Mulder WJ, Griffioen AW, Strijkers GJ, Cormode DP, Nicolay K, Fayad ZA. Magnetic and fluorescent nanoparticles for multimodality imaging. Nanomedicine (Lond). 2007; 2: 307-24.
37. Mulder WJ, Strijkers GJ, van Tilborg GA, Griffioen AW, Nicolay K. Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed. 2006; 19: 142-64.
38. Adibhatla RM. Citicoline in stroke and TBI clinical trials. Nat Rev Neurol. 2013; 9: 173.
39. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193: 265-75.
40. Hutchinson FJ, Francis SE, Lyle IG, Jones MN. The characterisation of liposomes with covalently attached proteins. Biochim Biophys Acta. 1989; 978: 17-24.
41. de Freitas MS, Spohr TC, Benedito AB, Caetano MS, Margulis B, Lopes UG, et al. Neurite outgrowth is impaired on HSP70-positive astrocytes through a mechanism that requires NF-kappaB activation. Brain Res. 2002; 958: 359-70.
42. Hurtado O, Moro MA, Cárdenas A, Sánchez V, Fernández-Tomé P, Leza JC, et al. Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport. Neurobiology of Disease. 2005; 18: 336-45.
43. Agulla J, Argibay B, Perez-Mato M, Brea D, Ramos-Cabrer P, Castillo J. [Comparison of the lesion produced by permanent focal cerebral ischaemia in three animal models using magnetic resonance imaging]. Rev Neurol. 2011; 53: 265-74.
44. Wegener S, Weber R, Ramos-Cabrer P, Uhlenkueken U, Sprenger C, Wiedermann D, et al. Temporal profile of T2-weighted MRI distinguishes between pannecrosis and selective neuronal death after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab. 2006; 26: 38-47.
45. Shigeno T, Teasdale GM, McCulloch J, Graham DI. Recirculation model following MCA occlusion in rats. Cerebral blood flow, cerebrovascular permeability, and brain edema. J Neurosurg. 1985; 63: 272-7.
46. Hak S, Sanders HM, Agrawal P, Langereis S, Grull H, Keizer HM, et al. A high relaxivity Gd(III)DOTA-DSPE-based liposomal contrast agent for magnetic resonance imaging. Eur J Pharm Biopharm. 2009; 72: 397-404.
47. Rouser G, Fkeischer S, Yamamoto A. Two dimensional then layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids. 1970; 5: 494-6.
48. Ramagli LS, Capetillo S, Becker FF, Rodriguez LV. Alterations in nonhistone chromatin proteins during hepatocarcinogenesis induced by diverse acting carcinogens. Carcinogenesis. 1985; 6: 367-75.
49. Brea D, Rodriguez-Gonzalez R, Sobrino T, Rodriguez-Yanez M, Blanco M, Castillo J. Proteomic analysis shows differential protein expression in endothelial progenitor cells between healthy subjects and ischemic stroke patients. Neurol Res. 2011; 33: 1057-63.
50. McCarthy KD, de Vellis J. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol. 1980; 85: 890-902.
51. Haacke EM, Brown RW, Thompson MR, Venkatesan R. Magnetic resonance imaging : physical principles and sequence design. New York ; CHichester: J. Wiley & Sons; 1999.